AAPL299.23+1.22 (+0.41%) ▲|ABBV229.90+13.41 (+6.19%) ▲|ABT88.22-0.19 (-0.21%) ▼|ACN119.17-8.82 (-6.89%) ▼|ADBE192.21-2.95 (-1.51%) ▼|AMAT622.55+5.44 (+0.88%) ▲|AMD545.39+8.02 (+1.49%) ▲|AMGN343.49+5.89 (+1.74%) ▲|AMT176.87+0.82 (+0.47%) ▲|AMZN234.41-9.99 (-4.09%) ▼|AVGO394.63-16.72 (-4.06%) ▼|AXP336.49-1.51 (-0.45%) ▼|BA220.85-1.87 (-0.84%) ▼|BAC57.32+1.12 (+1.98%) ▲|BKNG167.98-3.80 (-2.21%) ▼|BLK1,046.72-3.38 (-0.32%) ▼|BMY54.41+0.41 (+0.75%) ▲|BNY145.86+2.23 (+1.55%) ▲|BRK-B489.03-0.43 (-0.09%) ▼|C145.35+2.29 (+1.60%) ▲|CAT1,017.74+31.92 (+3.24%) ▲|CL89.69+0.21 (+0.23%) ▲|CMCSA22.40-0.04 (-0.16%) ▼|COF200.90-0.64 (-0.32%) ▼|COP109.38+1.64 (+1.52%) ▲|COST948.42-3.03 (-0.32%) ▼|CRM149.11-2.67 (-1.76%) ▼|CSCO121.19+1.65 (+1.38%) ▲|CVS101.85+3.53 (+3.59%) ▲|CVX175.00+1.37 (+0.79%) ▲|DE596.83+7.59 (+1.29%) ▲|DHR177.81+0.64 (+0.36%) ▲|DIS101.91-1.99 (-1.91%) ▼|DUK124.26+0.40 (+0.32%) ▲|EMR149.71-0.95 (-0.63%) ▼|FDX327.69+2.71 (+0.83%) ▲|GD343.06-6.95 (-1.99%) ▼|GE357.43-0.21 (-0.06%) ▼|GEV1,126.04+16.31 (+1.47%) ▲|GILD124.53+0.77 (+0.62%) ▲|GM80.88+1.59 (+2.01%) ▲|GOOG347.18-20.28 (-5.52%) ▼|GOOGL347.82-20.21 (-5.49%) ▼|GS1,098.72+2.16 (+0.20%) ▲|HD326.72-7.56 (-2.26%) ▼|HON228.36-0.66 (-0.29%) ▼|IBM246.50-2.60 (-1.04%) ▼|INTC140.81+6.82 (+5.09%) ▲|INTU256.53-10.47 (-3.92%) ▼|ISRG401.95-4.83 (-1.19%) ▼|JNJ230.40+2.01 (+0.88%) ▲|JPM331.90+6.68 (+2.05%) ▲|KO79.84+0.45 (+0.57%) ▲|LIN514.18+2.03 (+0.40%) ▲|LLY1,104.38+5.81 (+0.53%) ▲|LMT492.33-18.62 (-3.64%) ▼|LOW214.13-8.07 (-3.63%) ▼|LRCX395.18+6.14 (+1.58%) ▲|MA483.72-6.07 (-1.24%) ▼|MCD270.80-7.82 (-2.81%) ▼|MDLZ59.85-0.27 (-0.45%) ▼|MDT79.17-0.17 (-0.21%) ▼|META565.20-12.02 (-2.08%) ▼|MMM162.45+1.85 (+1.15%) ▲|MO69.65+0.53 (+0.76%) ▲|MRK114.75+0.88 (+0.77%) ▲|MS227.19+4.02 (+1.80%) ▲|MSFT370.13-9.27 (-2.44%) ▼|MU1,194.66+60.67 (+5.35%) ▲|NEE86.60-0.16 (-0.18%) ▼|NFLX72.86-4.52 (-5.84%) ▼|NKE43.21-2.00 (-4.41%) ▼|NOW92.05-2.99 (-3.15%) ▼|NVDA208.65-2.04 (-0.97%) ▼|ORCL175.26-9.04 (-4.90%) ▼|PEP140.70-1.33 (-0.93%) ▼|PFE25.01-0.21 (-0.81%) ▼|PG148.80-1.58 (-1.05%) ▼|PLTR119.62-8.86 (-6.89%) ▼|PM173.53-4.87 (-2.73%) ▼|QCOM222.21-3.90 (-1.72%) ▼|RTX182.46-3.14 (-1.69%) ▼|SBUX100.00-0.65 (-0.65%) ▼|SCHW92.03+0.33 (+0.35%) ▲|SO93.86+0.77 (+0.82%) ▲|SPG213.67+2.34 (+1.11%) ▲|T22.17+0.16 (+0.70%) ▲|TMO461.89-2.72 (-0.59%) ▼|TMUS181.05-0.62 (-0.34%) ▼|TSLA405.86+5.37 (+1.34%) ▲|TXN328.55+5.69 (+1.76%) ▲|UBER71.74+0.10 (+0.14%) ▲|UNH408.36+7.40 (+1.84%) ▲|UNP259.79+2.91 (+1.13%) ▲|UPS107.50+2.64 (+2.52%) ▲|USB58.58+0.44 (+0.75%) ▲|V326.67-0.57 (-0.17%) ▼|VZ45.41+0.04 (+0.09%) ▲|WFC83.81+1.61 (+1.95%) ▲|WMT117.20+0.02 (+0.02%) ▲|XOM138.48+0.67 (+0.49%) ▲|AAPL299.23+1.22 (+0.41%) ▲|ABBV229.90+13.41 (+6.19%) ▲|ABT88.22-0.19 (-0.21%) ▼|ACN119.17-8.82 (-6.89%) ▼|ADBE192.21-2.95 (-1.51%) ▼|AMAT622.55+5.44 (+0.88%) ▲|AMD545.39+8.02 (+1.49%) ▲|AMGN343.49+5.89 (+1.74%) ▲|AMT176.87+0.82 (+0.47%) ▲|AMZN234.41-9.99 (-4.09%) ▼|AVGO394.63-16.72 (-4.06%) ▼|AXP336.49-1.51 (-0.45%) ▼|BA220.85-1.87 (-0.84%) ▼|BAC57.32+1.12 (+1.98%) ▲|BKNG167.98-3.80 (-2.21%) ▼|BLK1,046.72-3.38 (-0.32%) ▼|BMY54.41+0.41 (+0.75%) ▲|BNY145.86+2.23 (+1.55%) ▲|BRK-B489.03-0.43 (-0.09%) ▼|C145.35+2.29 (+1.60%) ▲|CAT1,017.74+31.92 (+3.24%) ▲|CL89.69+0.21 (+0.23%) ▲|CMCSA22.40-0.04 (-0.16%) ▼|COF200.90-0.64 (-0.32%) ▼|COP109.38+1.64 (+1.52%) ▲|COST948.42-3.03 (-0.32%) ▼|CRM149.11-2.67 (-1.76%) ▼|CSCO121.19+1.65 (+1.38%) ▲|CVS101.85+3.53 (+3.59%) ▲|CVX175.00+1.37 (+0.79%) ▲|DE596.83+7.59 (+1.29%) ▲|DHR177.81+0.64 (+0.36%) ▲|DIS101.91-1.99 (-1.91%) ▼|DUK124.26+0.40 (+0.32%) ▲|EMR149.71-0.95 (-0.63%) ▼|FDX327.69+2.71 (+0.83%) ▲|GD343.06-6.95 (-1.99%) ▼|GE357.43-0.21 (-0.06%) ▼|GEV1,126.04+16.31 (+1.47%) ▲|GILD124.53+0.77 (+0.62%) ▲|GM80.88+1.59 (+2.01%) ▲|GOOG347.18-20.28 (-5.52%) ▼|GOOGL347.82-20.21 (-5.49%) ▼|GS1,098.72+2.16 (+0.20%) ▲|HD326.72-7.56 (-2.26%) ▼|HON228.36-0.66 (-0.29%) ▼|IBM246.50-2.60 (-1.04%) ▼|INTC140.81+6.82 (+5.09%) ▲|INTU256.53-10.47 (-3.92%) ▼|ISRG401.95-4.83 (-1.19%) ▼|JNJ230.40+2.01 (+0.88%) ▲|JPM331.90+6.68 (+2.05%) ▲|KO79.84+0.45 (+0.57%) ▲|LIN514.18+2.03 (+0.40%) ▲|LLY1,104.38+5.81 (+0.53%) ▲|LMT492.33-18.62 (-3.64%) ▼|LOW214.13-8.07 (-3.63%) ▼|LRCX395.18+6.14 (+1.58%) ▲|MA483.72-6.07 (-1.24%) ▼|MCD270.80-7.82 (-2.81%) ▼|MDLZ59.85-0.27 (-0.45%) ▼|MDT79.17-0.17 (-0.21%) ▼|META565.20-12.02 (-2.08%) ▼|MMM162.45+1.85 (+1.15%) ▲|MO69.65+0.53 (+0.76%) ▲|MRK114.75+0.88 (+0.77%) ▲|MS227.19+4.02 (+1.80%) ▲|MSFT370.13-9.27 (-2.44%) ▼|MU1,194.66+60.67 (+5.35%) ▲|NEE86.60-0.16 (-0.18%) ▼|NFLX72.86-4.52 (-5.84%) ▼|NKE43.21-2.00 (-4.41%) ▼|NOW92.05-2.99 (-3.15%) ▼|NVDA208.65-2.04 (-0.97%) ▼|ORCL175.26-9.04 (-4.90%) ▼|PEP140.70-1.33 (-0.93%) ▼|PFE25.01-0.21 (-0.81%) ▼|PG148.80-1.58 (-1.05%) ▼|PLTR119.62-8.86 (-6.89%) ▼|PM173.53-4.87 (-2.73%) ▼|QCOM222.21-3.90 (-1.72%) ▼|RTX182.46-3.14 (-1.69%) ▼|SBUX100.00-0.65 (-0.65%) ▼|SCHW92.03+0.33 (+0.35%) ▲|SO93.86+0.77 (+0.82%) ▲|SPG213.67+2.34 (+1.11%) ▲|T22.17+0.16 (+0.70%) ▲|TMO461.89-2.72 (-0.59%) ▼|TMUS181.05-0.62 (-0.34%) ▼|TSLA405.86+5.37 (+1.34%) ▲|TXN328.55+5.69 (+1.76%) ▲|UBER71.74+0.10 (+0.14%) ▲|UNH408.36+7.40 (+1.84%) ▲|UNP259.79+2.91 (+1.13%) ▲|UPS107.50+2.64 (+2.52%) ▲|USB58.58+0.44 (+0.75%) ▲|V326.67-0.57 (-0.17%) ▼|VZ45.41+0.04 (+0.09%) ▲|WFC83.81+1.61 (+1.95%) ▲|WMT117.20+0.02 (+0.02%) ▲|XOM138.48+0.67 (+0.49%) ▲|
22.6 C
New York
Monday, June 22, 2026

Tag: investor

newssourceFORcompanyinformationcontent1marketreleases

PHREESIA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Phreesia, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PHR

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Phreesia, Inc. (NYSE: PHR) between May 8, 2025 and March 30, 2026, inclusive (the “Class Period”), of the important July 13, 2026 lead plaintiff deadline.

BABCOCK & WILCOX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Babcock & Wilcox Enterprises, Inc. Investors to Secure Counsel Before Important June 15 Deadline in...

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Babcock & Wilcox Enterprises, Inc. (“B&W”) (NYSE: BW) between November 5, 2025 and March 11, 2026, inclusive (the “Class Period”), of the important June 15, 2026 lead plaintiff deadline.

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

Rosen Law Firm Encourages TruBridge, Inc. Investors to Inquire About Securities Class Action Investigation – TBRG

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of TruBridge, Inc. (NASDAQ: TBRG) resulting from allegations that TruBridge may have issued materially misleading business information to the investing public.

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release

COPENHAGEN, Denmark; June 13, 2026

Kos Biotechnology Partners Announces Third Closing of Global Life Sciences Fund at $123 Million

NEW YORK and ATHENS, Greece, June 13, 2026 /PRNewswire/ -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm bridging the US biopharma...

Kos Biotechnology Partners Announces Third Closing of Global Life Sciences Fund at $123 Million

NEW YORK and ATHENS, Greece, June 13, 2026 /PRNewswire/ -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm bridging the US biopharma...

NASDAQ: WGS: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against GeneDx Holdings Corp. (WGS)

Did you buy WGS securities between April 16, 2025, and May 4, 2026?

MANH Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Manhattan Associates, Inc. – MANH

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. (NASDAQ: MANH).

BTGO EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds BitGo Holdings (BTGO) Investors of Securities Class Action Lawsuit Deadline on August 7, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In BitGo To Contact Him Directly To Discuss Their Options

CALX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Calix (CALX) Investors of Securities Class Action Lawsuit Deadline on July 27, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Calix To Contact Him Directly To Discuss Their Options

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

Defiance ETFs Announces Temporary Trading Halt of the Defiance Daily 2X Space ETF (SPCL) on Cboe BZX Exchange, Inc.

Defiance ETFs Announces Temporary Trading Halt of the Defiance Daily 2X Space ETF (SPCL) on Cboe BZX Exchange, Inc.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInvestor

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers